HRP20030104A2 - Therapeutic combination - Google Patents

Therapeutic combination Download PDF

Info

Publication number: HRP20030104A2
Authority: HR; Croatia
Prior art keywords: pharmaceutically acceptable; trifluoromethyl; treatment; ethyl; mammals
Prior art date: 2000-08-15

Application number

HR20030104A

Other languages

English (en)

Croatian (hr)

Inventor

Charles Lester Shear

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-15

Filing date

2003-02-13

Publication date

2003-04-30

2003-02-13 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-04-30 Publication of HRP20030104A2 publication Critical patent/HRP20030104A2/hr

Links

230000001225 therapeutic effect Effects 0.000 title claims description 29
150000003839 salts Chemical class 0.000 claims description 55
238000011282 treatment Methods 0.000 claims description 53
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 51
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 51
229960005370 atorvastatin Drugs 0.000 claims description 51
150000001875 compounds Chemical class 0.000 claims description 50
241000124008 Mammalia Species 0.000 claims description 31
230000003143 atherosclerotic effect Effects 0.000 claims description 31
-1 ethyl ester [2R,4S]4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acids Chemical class 0.000 claims description 31
239000000825 pharmaceutical preparation Substances 0.000 claims description 28
201000001320 Atherosclerosis Diseases 0.000 claims description 25
125000004494 ethyl ester group Chemical group 0.000 claims description 24
238000000034 method Methods 0.000 claims description 24
206010002383 Angina Pectoris Diseases 0.000 claims description 20
239000003085 diluting agent Substances 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 17
239000003937 drug carrier Substances 0.000 claims description 16
230000000694 effects Effects 0.000 claims description 16
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
JRBOFAXVGHMLMM-APWZRJJASA-N (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylic acid Chemical compound COC(=O)N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(O)=O)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JRBOFAXVGHMLMM-APWZRJJASA-N 0.000 claims description 12
208000019622 heart disease Diseases 0.000 claims description 11
239000002552 dosage form Substances 0.000 claims description 9
238000011161 development Methods 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 claims description 4
239000003981 vehicle Substances 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims 8
239000001257 hydrogen Substances 0.000 claims 8
150000002431 hydrogen Chemical group 0.000 claims 3
230000001315 anti-hyperlipaemic effect Effects 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
239000000203 mixture Substances 0.000 description 39
239000002207 metabolite Substances 0.000 description 24
150000002632 lipids Chemical class 0.000 description 23
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 19
229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 19
208000029078 coronary artery disease Diseases 0.000 description 19
239000000243 solution Substances 0.000 description 19
108010010234 HDL Lipoproteins Proteins 0.000 description 17
102000015779 HDL Lipoproteins Human genes 0.000 description 17
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
201000010099 disease Diseases 0.000 description 13
241000283153 Cetacea Species 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
150000002596 lactones Chemical class 0.000 description 12
108010028554 LDL Cholesterol Proteins 0.000 description 11
108010007622 LDL Lipoproteins Proteins 0.000 description 11
102000007330 LDL Lipoproteins Human genes 0.000 description 11
239000002253 acid Substances 0.000 description 11
229940079593 drug Drugs 0.000 description 11
239000003814 drug Substances 0.000 description 11
OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 10
108010023302 HDL Cholesterol Proteins 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
229960001770 atorvastatin calcium Drugs 0.000 description 10
235000019441 ethanol Nutrition 0.000 description 10
239000007787 solid Substances 0.000 description 10
238000012360 testing method Methods 0.000 description 10
241000282412 Homo Species 0.000 description 9
239000013078 crystal Substances 0.000 description 9
239000000843 powder Substances 0.000 description 9
238000005160 1H NMR spectroscopy Methods 0.000 description 8
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
230000000747 cardiac effect Effects 0.000 description 8
210000001715 carotid artery Anatomy 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
230000002093 peripheral effect Effects 0.000 description 8
238000011160 research Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
208000031226 Hyperlipidaemia Diseases 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
210000004351 coronary vessel Anatomy 0.000 description 7
238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
239000002904 solvent Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
230000002411 adverse Effects 0.000 description 6
239000012267 brine Substances 0.000 description 6
230000007211 cardiovascular event Effects 0.000 description 6
235000005911 diet Nutrition 0.000 description 6
230000037213 diet Effects 0.000 description 6
238000006073 displacement reaction Methods 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
239000000463 material Substances 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000002265 prevention Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 5
108010078791 Carrier Proteins Proteins 0.000 description 5
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 5
238000002483 medication Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
230000008569 process Effects 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
238000012216 screening Methods 0.000 description 5
238000003756 stirring Methods 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
238000002604 ultrasonography Methods 0.000 description 5
QOTDBJKZKHHPCY-SCZZXKLOSA-N (2r,4s)-4-amino-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylic acid Chemical compound FC(F)(F)C1=CC=C2N(C(O)=O)[C@H](CC)C[C@H](N)C2=C1 QOTDBJKZKHHPCY-SCZZXKLOSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 4
208000032928 Dyslipidaemia Diseases 0.000 description 4
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
239000000006 Nitroglycerin Substances 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
108010062497 VLDL Lipoproteins Proteins 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
238000003556 assay Methods 0.000 description 4
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
229960003711 glyceryl trinitrate Drugs 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
238000000386 microscopy Methods 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
150000002823 nitrates Chemical class 0.000 description 4
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
238000008214 LDL Cholesterol Methods 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
208000017170 Lipid metabolism disease Diseases 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
238000002399 angioplasty Methods 0.000 description 3
230000003257 anti-anginal effect Effects 0.000 description 3
230000000879 anti-atherosclerotic effect Effects 0.000 description 3
SHZPNDRIDUBNMH-NIJVSVLQSA-L atorvastatin calcium trihydrate Chemical compound O.O.O.[Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SHZPNDRIDUBNMH-NIJVSVLQSA-L 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
229960001231 choline Drugs 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 3
125000005456 glyceride group Chemical group 0.000 description 3
150000004677 hydrates Chemical class 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 3
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
238000010191 image analysis Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000011835 investigation Methods 0.000 description 3
229940002661 lipitor Drugs 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
HVOAACKKZXUIKP-UHFFFAOYSA-N n-[1-(benzotriazol-1-yl)propyl]-4-(trifluoromethyl)aniline Chemical compound N1=NC2=CC=CC=C2N1C(CC)NC1=CC=C(C(F)(F)F)C=C1 HVOAACKKZXUIKP-UHFFFAOYSA-N 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
229960002855 simvastatin Drugs 0.000 description 3
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000012453 solvate Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000009662 stress testing Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
229960000281 trometamol Drugs 0.000 description 3
VYLKEIFSWPITNN-WBVHZDCISA-N (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylic acid Chemical compound N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(O)=O)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VYLKEIFSWPITNN-WBVHZDCISA-N 0.000 description 2
XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
MVODTGURFNTEKX-UHFFFAOYSA-N 2-bromo-n-(2-bromoethyl)-n-(thiophen-2-ylmethyl)ethanamine;hydrobromide Chemical compound Br.BrCCN(CCBr)CC1=CC=CS1 MVODTGURFNTEKX-UHFFFAOYSA-N 0.000 description 2
SRLPVLMCBOPWIE-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n-(3-hydroxyphenyl)-4-phenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC(O)=C1 SRLPVLMCBOPWIE-KAYWLYCHSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
208000020446 Cardiac disease Diseases 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229910004373 HOAc Inorganic materials 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
MNECBMZJZFGTIK-JWQCQUIFSA-N O-Hydroxyatorvastatin lactone Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1O MNECBMZJZFGTIK-JWQCQUIFSA-N 0.000 description 2
KDJMDZSAAFACAM-KAYWLYCHSA-N P-Hydroxyatorvastatin lactone Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=C(O)C=C1 KDJMDZSAAFACAM-KAYWLYCHSA-N 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
150000001840 cholesterol esters Chemical class 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000002586 coronary angiography Methods 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
229940043237 diethanolamine Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
235000019371 penicillin G benzathine Nutrition 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229960002965 pravastatin Drugs 0.000 description 2
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000011084 recovery Methods 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
230000000391 smoking effect Effects 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000003325 tomography Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
IAESBDQXEFYNMT-QAPCUYQASA-N (2r,4s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-amine Chemical compound N([C@H]1C[C@H](NC2=CC=C(C=C21)C(F)(F)F)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IAESBDQXEFYNMT-QAPCUYQASA-N 0.000 description 1
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
LDWLIXZSDPXYDR-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC(C=O)=CC(C(F)(F)F)=C1 LDWLIXZSDPXYDR-UHFFFAOYSA-N 0.000 description 1
101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
101150102415 Apob gene Proteins 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010071200 Carbohydrate intolerance Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241001085205 Prenanthella exigua Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
238000011256 aggressive treatment Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003529 anticholesteremic agent Substances 0.000 description 1
229940127226 anticholesterol agent Drugs 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
YGBQZFPEMRCQRY-UHFFFAOYSA-N benzyl n-ethenylcarbamate Chemical compound C=CNC(=O)OCC1=CC=CC=C1 YGBQZFPEMRCQRY-UHFFFAOYSA-N 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000036996 cardiovascular health Effects 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000007408 cone-beam computed tomography Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000012045 crude solution Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
235000021045 dietary change Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
SLFUXNFVAANERW-UHFFFAOYSA-N ethyl hexanoate;potassium Chemical compound [K].CCCCCC(=O)OCC SLFUXNFVAANERW-UHFFFAOYSA-N 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
229960003765 fluvastatin Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000007446 glucose tolerance test Methods 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
229960000201 isosorbide dinitrate Drugs 0.000 description 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
229960003827 isosorbide mononitrate Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
AXLHVTKGDPVANO-UHFFFAOYSA-N methyl 2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)C(N)CNC(=O)OC(C)(C)C AXLHVTKGDPVANO-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960005141 piperazine Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000207 pro-atherogenic effect Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
238000012954 risk control Methods 0.000 description 1
235000021003 saturated fats Nutrition 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
238000007614 solvation Methods 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
235000021076 total caloric intake Nutrition 0.000 description 1
239000006211 transdermal dosage form Substances 0.000 description 1
230000008733 trauma Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000021081 unsaturated fats Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)

HR20030104A 2000-08-15 2003-02-13 Therapeutic combination HRP20030104A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22523800P	2000-08-15	2000-08-15
PCT/IB2001/001309 WO2002013797A2 (fr)	2000-08-15	2001-07-23	Combinaison therapeutique

Publications (1)

Publication Number	Publication Date
HRP20030104A2 true HRP20030104A2 (en)	2003-04-30

Family

ID=22844100

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20030104A HRP20030104A2 (en)	2000-08-15	2003-02-13	Therapeutic combination

Country Status (27)

Country	Link
US (1)	US20020035125A1 (fr)
EP (1)	EP1309329A2 (fr)
JP (1)	JP2004506008A (fr)
KR (1)	KR20030069983A (fr)
CN (1)	CN1735416A (fr)
AP (1)	AP2003002743A0 (fr)
AU (1)	AU2001270937A1 (fr)
BG (1)	BG107515A (fr)
BR (1)	BR0113200A (fr)
CA (1)	CA2419406A1 (fr)
CZ (1)	CZ2003390A3 (fr)
DZ (1)	DZ3409A1 (fr)
EA (1)	EA200300155A1 (fr)
EC (1)	ECSP034478A (fr)
HR (1)	HRP20030104A2 (fr)
HU (1)	HUP0303083A3 (fr)
IL (1)	IL154348A0 (fr)
IS (1)	IS6700A (fr)
MX (1)	MXPA03001419A (fr)
NO (1)	NO20030725D0 (fr)
PA (1)	PA8525301A1 (fr)
PE (1)	PE20020340A1 (fr)
SK (1)	SK1742003A3 (fr)
SV (1)	SV2003000600A (fr)
TN (1)	TNSN01125A1 (fr)
UY (1)	UY26883A1 (fr)
WO (1)	WO2002013797A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030044459A1 (en) *	2001-09-04	2003-03-06	Pfizer Inc.	Biomodulated multiparticulate formulations
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
EP1581210B1 (fr)	2002-12-20	2008-03-19	Pfizer Products Inc.	Formes posologiques comprenant un inhibiteur de la cetp et un inhibiteur de la hmg-coa reductase
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ES2310676T3 (es) *	2002-12-20	2009-01-16	Pfizer Products Inc.	Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de hmg-coa reductasa.
TWI393560B (zh) *	2003-05-02	2013-04-21	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CN1812983A (zh) *	2003-05-30	2006-08-02	兰贝克赛实验室有限公司	取代的吡咯衍生物及其作为hmg－co抑制剂的用途
CA2534371A1 (fr) *	2003-08-04	2005-02-10	Pfizer Products Inc.	Formes posologiques d'inhibiteurs de la proteine de transfert d'ester de cholesteryle et d'inhibiteurs de la hmg-coa-reductase
SG146695A1 (en)	2003-09-26	2008-10-30	Japan Tobacco Inc	Method of inhibiting remnant lipoprotein production
EP1737811B1 (fr) *	2004-04-13	2016-08-10	Merck Sharp & Dohme Corp.	Inhibiteurs de cetp
EP1845953A1 (fr) *	2005-02-03	2007-10-24	Pfizer Products Incorporated	Formes de dosage assurant la liberation controlee et instantanee d'inhibiteurs de proteines de transfert d'ester de cholesteryle et la liberation instantanee d'inhibiteurs de hmg-coa reductase
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
EP3187182B1 (fr)	2008-09-02	2021-03-03	Amarin Pharmaceuticals Ireland Limited	Compositions pharmaceutiques contenant de l'acide eicosapentaénoïque et de l'acide nicotinique, et leurs procédés d'utilisation
EP2379547A1 (fr)	2008-12-16	2011-10-26	Schering Corporation	Dérivés de pyridopyrimidine et leurs procédés d'utilisation
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
CA3089847C (fr)	2009-02-10	2024-04-09	Amarin Pharmaceuticals Ireland Limited	Utilisation d'acide icosapentanoique pour le traitement de l'hypertriglyceridemie
PL2424356T3 (pl)	2009-04-29	2018-03-30	Amarin Pharmaceuticals Ireland Limited	Stabilna farmaceutyczna kompozycja i sposoby jej stosowania
CN106822080A (zh)	2009-04-29	2017-06-13	阿马里纳药物爱尔兰有限公司	含有epa和心血管剂的药物组合物以及使用其的方法
CN106074486A (zh)	2009-06-15	2016-11-09	阿马里纳药物爱尔兰有限公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
SG10201405994UA (en)	2009-09-23	2014-10-30	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en)	2010-11-29	2019-10-25	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (fr)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Méthodes de traitement de l'hypertriglycéridémie
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
JP6307442B2 (ja)	2012-01-06	2018-04-04	アマリンファーマシューティカルスアイルランドリミテッド	対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
MX2020008890A (es)	2012-06-29	2022-08-15	Amarin Pharmaceuticals Ie Ltd	Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
US20150265566A1 (en)	2012-11-06	2015-09-24	Amarin Pharmaceuticals Ireland Limited	Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh)	2017-05-19	2019-01-01	愛爾蘭商艾瑪琳製藥愛爾蘭有限公司	用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr)	2018-09-24	2020-09-02	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU2157400A (en) *	1998-12-23	2000-07-31	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
US20020028826A1 (en) *	2000-06-15	2002-03-07	Robl Jeffrey A.	HMG-CoA reductase inhibitors and method

2001
- 2001-07-23 IL IL15434801A patent/IL154348A0/xx unknown
- 2001-07-23 MX MXPA03001419A patent/MXPA03001419A/es not_active Application Discontinuation
- 2001-07-23 JP JP2002518943A patent/JP2004506008A/ja not_active Withdrawn
- 2001-07-23 CA CA002419406A patent/CA2419406A1/fr not_active Abandoned
- 2001-07-23 CN CNA018150667A patent/CN1735416A/zh active Pending
- 2001-07-23 CZ CZ2003390A patent/CZ2003390A3/cs unknown
- 2001-07-23 HU HU0303083A patent/HUP0303083A3/hu unknown
- 2001-07-23 EA EA200300155A patent/EA200300155A1/ru unknown
- 2001-07-23 KR KR10-2003-7002220A patent/KR20030069983A/ko not_active Application Discontinuation
- 2001-07-23 AP APAP/P/2003/002743A patent/AP2003002743A0/en unknown
- 2001-07-23 WO PCT/IB2001/001309 patent/WO2002013797A2/fr not_active Application Discontinuation
- 2001-07-23 DZ DZ013409A patent/DZ3409A1/fr active
- 2001-07-23 AU AU2001270937A patent/AU2001270937A1/en not_active Abandoned
- 2001-07-23 EP EP01949825A patent/EP1309329A2/fr not_active Ceased
- 2001-07-23 SK SK174-2003A patent/SK1742003A3/sk not_active Application Discontinuation
- 2001-07-23 BR BR0113200-8A patent/BR0113200A/pt not_active IP Right Cessation
- 2001-08-14 SV SV2001000600A patent/SV2003000600A/es not_active Application Discontinuation
- 2001-08-14 PE PE2001000810A patent/PE20020340A1/es not_active Application Discontinuation
- 2001-08-14 UY UY26883A patent/UY26883A1/es not_active Application Discontinuation
- 2001-08-14 US US09/929,862 patent/US20020035125A1/en not_active Abandoned
- 2001-08-14 TN TNTNSN01125A patent/TNSN01125A1/fr unknown
- 2001-08-14 PA PA20018525301A patent/PA8525301A1/es unknown
2003
- 2003-01-27 IS IS6700A patent/IS6700A/is unknown
- 2003-02-03 BG BG107515A patent/BG107515A/xx unknown
- 2003-02-13 EC EC2003004478A patent/ECSP034478A/es unknown
- 2003-02-13 HR HR20030104A patent/HRP20030104A2/hr not_active Application Discontinuation
- 2003-02-14 NO NO20030725A patent/NO20030725D0/no unknown

Also Published As

Publication number	Publication date
UY26883A1 (es)	2002-03-22
TNSN01125A1 (fr)	2005-11-10
EP1309329A2 (fr)	2003-05-14
AU2001270937A1 (en)	2002-02-25
BG107515A (en)	2003-09-30
DZ3409A1 (fr)	2002-02-21
WO2002013797A3 (fr)	2003-03-13
CN1735416A (zh)	2006-02-15
CZ2003390A3 (en)	2004-03-17
SV2003000600A (es)	2003-01-13
WO2002013797A2 (fr)	2002-02-21
MXPA03001419A (es)	2003-06-06
HUP0303083A3 (en)	2005-05-30
IS6700A (is)	2003-01-27
CA2419406A1 (fr)	2002-02-21
SK1742003A3 (en)	2004-06-08
NO20030725D0 (no)	2003-02-14
KR20030069983A (ko)	2003-08-27
ECSP034478A (es)	2003-03-31
JP2004506008A (ja)	2004-02-26
PE20020340A1 (es)	2002-05-10
PA8525301A1 (es)	2002-04-25
HUP0303083A2 (hu)	2003-12-29
IL154348A0 (en)	2003-09-17
US20020035125A1 (en)	2002-03-21
EA200300155A1 (ru)	2003-08-28
AP2003002743A0 (en)	2003-03-31
BR0113200A (pt)	2003-09-16

Legal Events

Date	Code	Title	Description
2003-04-30	A1OB	Publication of a patent application
2004-06-29	OBST	Application withdrawn

Publication	Publication Date	Title
HRP20030104A2 (en)	2003-04-30	Therapeutic combination
EP1491193B1 (fr)	2006-07-12	Combinaisons thérapeutiques contenant de l'amlodipine et de l'atorvastatine
US7071206B2 (en)	2006-07-04	Agents for treating neurodegenerative disorders
AP1207A (en)	2003-09-20	Combination therapy.
JP2005041875A (ja)	2005-02-17	アトルバスタチンと血圧降下薬とを含む組み合わせ療法
CN102964302A (zh)	2013-03-13	***烷化合物
JP2003500473A (ja)	2003-01-07	アムロジピンおよびアトルバスタチンの相互塩
US20070149578A1 (en)	2007-06-28	Combination Therapy
EP1180102B9 (fr)	2005-03-02	Promedicaments communs d'amlodipine et d'atorvastatine
JP2002508320A (ja)	2002-03-19	スタチン−カルボキシアルキルエーテル配合物
OA12363A (en)	2006-05-16	Therapeutic combination of a CETP inhibitor and atTartrate salts of thiazolidinedione derivative. orvastatin.
WO2002020009A1 (fr)	2002-03-14	Compositions medicales
CN114377136A (zh)	2022-04-22	用于高脂血症治疗的联合用药物及其用途
WO2006011551A1 (fr)	2006-02-02	Composition pharmaceutique ayant une activité anti-artériosclérose